Clinics using biologic products, like any clinic using a medical product, should have an internal process for recording what happened, when, and in connection with which specific lot, independent of any assessment of whether the product caused the event. This recordkeeping exists so information is complete and timely if it is ever needed, not to assign cause in the moment.
FDA has repeatedly warned that products marketed outside an approved framework carry risks that may not be well characterized, and has published consumer-facing guidance describing the kinds of harm reported in connection with unapproved regenerative products. That context is part of why internal adverse-event records matter: a clinic's own records are what a regulator or counsel will review if something goes wrong, not the distributor's marketing materials.
This entry does not advise on clinical response to an adverse event and is not an instruction for diagnosis or treatment decisions. A clinic can ask a supplier whether it provides a contact point for reporting product-related concerns and a process for retrieving lot-specific records, such as a certificate of analysis or chain-of-custody file, if a regulator or legal counsel requests them.
Having a working adverse-event process in place before you need it is part of basic risk management for any clinic purchasing products in this category.